Search - tctmd.com

Displaying 501 - 520 of 1002

Sort: Relevancy | Date

No Very Late Scaffold Thrombosis Risk With Absorb BVS in China, Japan

News Conference News EuroPCR 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Michael O'Riordan

May 17, 2017

News Industry News

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

May 16, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Conference News EuroPCR 2017

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Michael O'Riordan

May 15, 2017

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Shelley Wood

May 12, 2017

News Features

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Michael O'Riordan

May 08, 2017

News Daily News

Absorb BVS Recalled in Australia From All Centers Not Studying Device

Shelley Wood

May 03, 2017

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

News Daily News

Same-Day Discharge After Elective PCI Grows More Popular but Still Not the Norm

Caitlin E. Cox

April 06, 2017

News Daily News

Absorb BVS Use Restricted in Europe

Michael O'Riordan

April 06, 2017

News Industry News

REVA Receives CE Mark for Fantom

April 04, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

News Industry News

REVA to Expand FANTOM II Trial to More Complex Cases

March 24, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

Caitlin E. Cox

March 18, 2017

News Daily News

FDA Gives Thumbs Up to Side Branch Stent for Bifurcation Lesions

Todd Neale

March 06, 2017

News Daily News

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

L.A. McKeown

March 02, 2017

News Conference News CRT 2017

Same-Day Discharge After Transradial PCI Safe, Feasible, With Significant Cost Savings

Michael O'Riordan

February 23, 2017

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

Increased Radial Access Is Not Associated With Worse Femoral Outcomes for PCI in UK

News Daily News

High-Volume Transradial PCI Centers Do Not Lose Femoral Skills: BCIS Registry

Michael O'Riordan

February 17, 2017

Advertisement

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Absorb BVS Recalled in Australia From All Centers Not Studying Device

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Same-Day Discharge After Elective PCI Grows More Popular but Still Not the Norm

Absorb BVS Use Restricted in Europe

REVA Receives CE Mark for Fantom

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

REVA to Expand FANTOM II Trial to More Complex Cases

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

FDA Gives Thumbs Up to Side Branch Stent for Bifurcation Lesions

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

Same-Day Discharge After Transradial PCI Safe, Feasible, With Significant Cost Savings

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

High-Volume Transradial PCI Centers Do Not Lose Femoral Skills: BCIS Registry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content